NewAmsterdam Pharma Co NV (FRA:KH6) EBITDA Margin % : -2,575.94% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NewAmsterdam Pharma Co NV's EBITDA for the six months ended in Dec. 2023 was €-87.38 Mil. NewAmsterdam Pharma Co NV's Revenue for the six months ended in Dec. 2023 was €3.39 Mil. Therefore, NewAmsterdam Pharma Co NV's EBITDA margin for the quarter that ended in Dec. 2023 was -2,575.94%.

NewAmsterdam Pharma Co NV EBITDA Margin % Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV EBITDA Margin % Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

-21.75

-1,255.18

NewAmsterdam Pharma Co NV Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial			-	58.54	-1,581.97	-785.06	-2,575.94

Competitive Comparison of NewAmsterdam Pharma Co NV's EBITDA Margin %

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's EBITDA Margin % falls into.

NewAmsterdam Pharma Co NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NewAmsterdam Pharma Co NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-162.182	/	12.921
	=	-1,255.18 %

NewAmsterdam Pharma Co NV's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-87.376	/	3.392
	=	-2,575.94 %

NewAmsterdam Pharma Co NV (FRA:KH6) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

NewAmsterdam Pharma Co NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

NAMS:USA KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines